Welcome to our dedicated page for ResMed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on ResMed stock.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in digital health and cloud-connected medical devices, focusing on innovative solutions that treat and prevent respiratory conditions like sleep apnea and COPD. By transforming patient care, ResMed empowers individuals to live healthier, higher-quality lives. Their diverse product portfolio includes flow generators, masks, and accessories designed to keep patients out of hospitals and manage chronic diseases effectively.
Operating in over 140 countries, ResMed’s cloud-connected medical devices provide data-driven insights used by patients, healthcare providers, and payers to deliver personalized and efficient healthcare. Their comprehensive out-of-hospital software platforms support professionals and caregivers, enhancing the quality of life and reducing healthcare costs. The company earns about two-thirds of its revenue from the Americas, with the remainder coming from Europe, Japan, and Australia.
In recent developments, ResMed successfully defended its intellectual property against a patent infringement claim by NYU, with the PTAB ruling in favor of ResMed on all challenged claims. This outcome underscores the company’s commitment to innovation, backed by over 9,500 issued or pending patents and designs.
ResMed also made headlines with a global field action to update guides for masks with magnets, ensuring user safety around medical implants. Their proactive approach and dedication to patient safety were evident as they addressed potential magnetic interference issues without necessitating a product recall.
Financially, ResMed continues to demonstrate strong growth. In the second quarter of fiscal year 2024, the company reported double-digit growth across its devices, masks, accessories, and residential care software businesses. This robust performance highlights ResMed’s strategic focus on expanding its product offerings and maintaining cost discipline.
ResMed's latest product launch, the AirCurve 11 series, further showcases their commitment to innovation. These bilevel PAP devices feature advanced digital technology to improve patient comfort and compliance, addressing challenges in CPAP therapy adaptation.
Continuing its leadership in respiratory care, ResMed actively participates in significant industry conferences such as the American Thoracic Society International Conference and SLEEP 2024, presenting crucial research on sleep disorders and their impact on health. This research supports the effectiveness of PAP therapy in reducing mortality and improving patient outcomes, solidifying ResMed’s role as a pioneer in the field.
With a clear focus on enhancing patient care through technology and innovation, ResMed is well-positioned to lead the expansion of sleep and respiratory health.
ResMed (NYSE: RMD, ASX: RMD) has expanded its board of directors to 11 members by appointing Christopher DelOrefice, the current CFO of Becton, Dickinson and Company (BD). DelOrefice brings over 30 years of strategic and operational finance expertise to ResMed's board. He will also serve on the board's audit committee. DelOrefice's appointment is effective immediately, and he will stand for re-election at ResMed's annual meeting on November 21, 2024.
Prior to joining BD, DelOrefice held various leadership roles at Johnson & Johnson, including vice president of investor relations and CFO of J&J's consumer and medical device business segments for North America. His experience also includes positions at AstraZeneca, AET Films, and Ametek. ResMed's CEO, Mick Farrell, praised DelOrefice's achievements and leadership capabilities, noting that his financial experience in healthcare and medical technology will complement the existing board members.
ResMed Inc. (NYSE: RMD, ASX: RMD) reported strong Q4 2024 results with year-over-year revenue growth of 9% to $1.2 billion. Key highlights include:
- Gross margin improved 350 bps to 58.5%
- Income from operations increased 38%
- Operating cash flow of $440 million
- Diluted EPS of $1.98; non-GAAP diluted EPS of $2.08
- Quarterly dividend increased 10% to $0.53 per share
For the full fiscal year 2024, ResMed achieved:
- Revenue growth of 11% to $4.7 billion
- Gross margin improvement of 90 bps to 56.7%
- Income from operations increase of 17%
- Operating cash flow of $1.4 billion
- Diluted EPS of $6.92; non-GAAP diluted EPS of $7.72
The company reported strong performance across all sectors, driven by high demand for its products and software solutions.
ResMed (NYSE: RMD, ASX: RMD) announces it will release its fourth quarter fiscal year 2024 earnings on August 1, 2024, after the NYSE closes. Management will host a webcast to discuss the financial and operational results. Investors and stakeholders will gain insights into the company's performance and future outlook.
ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of PAP therapy for Obstructive Sleep Apnea (OSA) and comorbid insomnia (COMISA). Key findings include a 31% reduction in hospitalizations and a 23% decrease in ER visits among COMISA patients adhering to PAP therapy. The research also revealed a 17% prevalence of insomnia in adults across North America, Latin America, and the Caribbean, and higher rates of depression in women with OSA. The studies underscore the importance of sleep health and PAP therapy in improving patient outcomes.
New research supported by ResMed, presented at the American Thoracic Society (ATS) 2024 International Conference, highlights the effectiveness of Positive Airway Pressure (PAP) therapy in reducing risks of death and hospitalization in patients with obstructive sleep apnea (OSA). Notable findings include a 37% reduction in mortality for PAP-treated OSA patients and a projection that OSA prevalence in the U.S. will rise by 26.7% among adults aged 30-70 by 2050. Additional studies reveal that adherence to GLP-1 medications correlates with higher PAP therapy usage, and adaptive servo-ventilation (ASV) therapy improves quality of life for patients with treatment-emergent central sleep apnea (TE-CSA) and opioid-induced central sleep apnea. The research underscores the critical role of PAP therapy in managing sleep disorders and improving cardiovascular health outcomes.
ResMed will present 26 abstracts at the American Thoracic Society (ATS) 2024 conference in San Diego, highlighting the increasing prevalence of obstructive sleep apnea (OSA) and the critical role of Positive Airway Pressure (PAP) therapy. Key sessions include studies on the impact of PAP therapy on hospitalization, mortality in OSA patients, and the prevalence of OSA into 2050. The event will showcase digital innovations and patient-centric approaches in respiratory care, featuring the latest ResMed products like the AirCurve 11 Bilevel Devices and the AirFit F40 CPAP mask.
ResMed (RMD) announced its participation in the RBCCM Global Healthcare Conference with key company executives discussing key topics. The event will be held on May 14, 2024, at InterContinental New York Barclay. More details and webcast access are available on ResMed's investor relations website.
FAQ
What is the current stock price of ResMed (RMD)?
What is the market cap of ResMed (RMD)?
What does ResMed Inc. specialize in?
Where does ResMed operate?
What are some of ResMed’s recent key developments?
How does ResMed ensure patient safety with its products?
What financial performance did ResMed report recently?
What innovations has ResMed introduced recently?
How does ResMed contribute to healthcare research?
What is ResMed’s approach to out-of-hospital care?
What kind of products does ResMed develop?
How does ResMed support its innovation?
